Tags : Konkuk University


Bridge Biotherapeutics Signs a License Agreement with Konkuk University for

Shots: Konkuk University to receive $0.25M upfront, ~$8.1M development and commercial milestones while Bridge Biotherapeutics to get WW exclusive license for the compound and will lead preclinical and development process of the therapy Additionally, in 2019, Bridge Biotherapeutics signed a license agreement with Boehringer Ingelheim to develop BBT-877, an autotaxin inhibitor targeting fibrosing interstitial lung […]Read More